Jim Van Meerten is an advisor to Marketocracy Capital Management and writes on financial subjects here and on Barchart Portfolio Blogs. He earned a BS in Accounting and Business Administration from Berry College; a Juris Doctorate from the Woodrow Wilson School of Law; and attended... More
- My company:
- Marketocracy Capital Management
- My blog:
- Barchart Portfolio Blogs
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
-
Instablogged Stocks
Stocks that instabloggers have most recently written about -
Latest Instablog Posts
- 1 The Global Race For Shale Development Is On
- 2 Empire Oil & Gas Continues Gas Production At...
- 3 Sun Resources' Director Snaps Up $60,000 Of ...
- 4 Optionity Daily Report 06/18/2013
- 5 Tuesday's Melt-Up, But Not New Highs Yet, As...
-
Top Instablogs
See all Top Instablogs »









Big Growth in Generic Drugs 0 comments
The big story is in the acquisition of the Arrow Group. Although the acquisition required the issuance of 17 million shares that dilutes earning per share, overall sales should benefit because it will allow the company to enter new over seas markets. Growth will come in new offerings of generic drugs in the areas of urology, birth control and a new generic version of Lipitor one of the largest selling brand names on the planet.
This is a momentum play and the stock hit 6 new highs in the last 30 days even in this soft market. The growth in price has been steady so it earned a 100% overall Barchart buy signal having buy signals on all 13 technical indicators. The stock appreciated 2.58% in the last 30 days and trades around 43.73 with a 50 day moving average of 42.18.
Investor sentiment is high as measured on Motley Fool with the CAPS members voting 148 to 17 that the stock will beat the market. The All Stars have similar feelings with a vote of 55 to 4.
Wall Street analysts have noticed this stock and have 5 buy and 9 hold reports published. They look for double digit growth in both sales and earnings. Sales are predicted to increase 25.80% this year and 11.10% next year. Earnings growth is forcasted to be 25.20% this year, 11.50% next year and a 5 year compounded growth rate of 10.42% annually.
This stock deserves your attention because:
Jim Van Meerten is an investor who writes on investing on Financial Tides and Barchart Portfolio Blogs. Please leave a comment below or email JimVanMeerten@gmail.com.
Disclosure: No positions in WPI at the time of publication
Other analyses by the same author:
Baidu -- BIDU
VeriSign -- VRSN
Chico's -- CHS
Disclosure: No positions in WPI at the time of publication
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
Share this Instablog
Latest Followers
StockTalks
-
$AMAT - 96% Barchart technical buy signals - 6 new highs and up 5.61% in the last month - Relative Strength Index 63.59%
1 day ago
-
$SPLS - 100% Barchart technical buy signals - 9 new highs and up 13.16% in the last month _ Relative Strength Index 77.71%
1 day ago
-
$SNDK - 100% Barchart technical buy signals - 4 new highs and up 2.52% in the last month - Relative Strength Index 64.91%
1 day ago
More »Latest Comments
Most Commented
Posts by Themes